Please login to the form below

Not currently logged in
Email:
Password:

Zostavax

This page shows the latest Zostavax news and features for those working in and with pharma, biotech and healthcare.

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck &Co. ... Shingrix could be used in patients who have previously received Zostavax.

Latest news

  • GSK’s shingles vaccine Shingrix claims US approval GSK’s shingles vaccine Shingrix claims US approval

    Becomes first alternative to Merck &Co’s Zostavax. GlaxoSmithKline has picked up its second approval for new shingles vaccine Shingrix, a potential blockbuster that is considered key to the company’s ... The FDA has approved Shingrix for the

  • GSK's Shingrix sails through FDA advisory committee GSK's Shingrix sails through FDA advisory committee

    It is increasingly common with advancing age. GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which remain ... In June, the company reported the results of a trial

  • GSK makes case for revaccination with Shingrix GSK makes case for revaccination with Shingrix

    The results of the Zoster-048 study met its primary objective of showing that people who had received the currently-approved vaccine - Merck &Co's Zostavax - at least five years previously ... after clinical data demonstrated the drug's greater efficacy

  • GSK files shingles vaccine Shingrix in Europe GSK files shingles vaccine Shingrix in Europe

    Blockbuster hopeful would compete with Merck &Co’s Zostavax.  . GlaxoSmithKline has submitted its shingles vaccine Shingrix for European marketing authorisation, following on the heels of its FDA filing last month. ... By contrast, Zostavax -

  • GSK's blockbuster hopeful Shingrix filed in US GSK's blockbuster hopeful Shingrix filed in US

    In contrast, Zostavax' efficacy is generally between 18% and 70% and is known to decline in older people. ... GSK is hoping that increased efficacy means it will be favoured ahead of Zostavax and also drive up vaccination rates against shingles, which

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics